IO Biotech(IOBT)
COPENHAGEN, DenmarkBiotechnology
Focus: IO Biotech is a Copenhagen-based public immuno-oncology biotech founded in 2012, focused on therapeutic cancer vaccines and combination approaches targeting PD-L1, IDO, and other immune checkpoints. The company operates as a clinical-stage biotech with a lean R&D-focused model and no commercial revenue.
Profile data last refreshed 6h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About IO Biotech
AI assessmentNot HiringNo open roles listed right now. Follow IO Biotech to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PD-L1/IDO Peptide Vaccine
High Risk Non-Muscle Invasive Bladder Urothelial CarcinomaClinical Trials (1)
NCT05843448IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
Phase 1Help build intelligence for IO Biotech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.